- 移动端
深圳欣博盛生物科技有限公司品牌商
16 年
手机商铺
商家活跃：
产品热度：
- NaN
- 0
- 0
- 2
- 2
全部产品
- 查看全部分类
- 欣博盛ELISA 试剂盒
- Vectorlabs
- GeneTex
- Peprotech
- Invivogen
- BioXcell
- FuGENE
- Prozyme
- Cayman
- Mirusbio
- ENZO(Alexis, Biomol, Assaydesign&stressgen)
- AbD Serotec
- Surmodics
- Millipore
- Metasystems
- Mabtech
- Proimmune
- Adipogen
- Bioporto
- Southern Biotech (SBA)
- Everest Biotech
- Chondrex
- IQ Products
- Atlas
- Detroit R&D
- StressMarq
- Cell Biolabs
- StrigoLab
- Synaptic Systems
- BioInnovatise
- Cosmo Bio
- Abwiz Bio
- Gerbu
- 蛋白
- 试剂类
- 抗体
- 分子化合物
- Cargille
- Antagen
- Nanoprobes
- Funakoshi
- Demeditec
- Enzo
- Fitzgerald
- Biovendor
- ICL
- Matreya
- PhaRNA
- Funakoshi
- Promise Advanced Proteomics
- Bioassay works
- NSJ Bio
- Aldevron
- CalBioreagents
- 3Helix
- 自产试剂盒
- TriLink
- Virostat
- Agilent
- Epicypher
- Jackson ImmunoResearch
推荐产品
公司新闻/正文
BioXCell newest 文献引用
552 人阅读发布时间：2020-09-15 11:59
The Journal of Immunology newest 发布的文献 ” Persistent Zika Virus Clinical Susceptibility despite Reduced Viral Burden in Mice with Expanded Virus-Specific CD8+ T Cells Primed by Recombinant Listeria monocytogenes” 使用了BioXCell的anti-mouse IFNAR-1抗体, 这篇文献研究数据强调了在开发针对寨卡病毒感染的疫苗中靶向其他适应性免疫成分的必要性。
摘要：Vaccines against Zika virus (ZIKV) infection that target CD8+ T cells are of considerable interest because Abs may enhance infection susceptibility. However, whether CD8+ T cells are protective or promote susceptibility to clinical infection symptoms remains uncertain. To more precisely investigate ZIKV-specific CD8+ T cells in isolation, we engineered a Listeria monocytogenes–based vector to express a single MHC class I–restricted immune dominant peptide, E294–302, from ZIKV envelope protein. We show accumulation of activated ZIKV-specific CD8+ T cells primed by recombinant L. monocytogenes is associated with reductions in circulating virus levels after ZIKV challenge in type I IFN receptor–deficient mice and wildtype mice administered neutralizing Abs against type I IFN receptor. Interestingly, susceptibility to ZIKV clinical infection including weight loss and mortality each persists and is neither significantly improved nor worsened compared with isogenic L. monocytogenes–primed control mice. These data demonstrating persistent ZIKV clinical susceptibility despite reduced viral burden in mice with expanded virus-specific CD8+ T cells highlights the need for targeting other adaptive immune components in developing vaccines against ZIKV infection.
文章链接：https://www.jimmunol.org/content/205/2/447
订购详情：
详情请咨询 BioXcell 中国授权代理-欣博盛生物科技
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：18024516375 香港: 852-69410778
代理品牌网站: www.nbs-bio.com
自主品牌网站: www.neobioscience.net
摘要：Vaccines against Zika virus (ZIKV) infection that target CD8+ T cells are of considerable interest because Abs may enhance infection susceptibility. However, whether CD8+ T cells are protective or promote susceptibility to clinical infection symptoms remains uncertain. To more precisely investigate ZIKV-specific CD8+ T cells in isolation, we engineered a Listeria monocytogenes–based vector to express a single MHC class I–restricted immune dominant peptide, E294–302, from ZIKV envelope protein. We show accumulation of activated ZIKV-specific CD8+ T cells primed by recombinant L. monocytogenes is associated with reductions in circulating virus levels after ZIKV challenge in type I IFN receptor–deficient mice and wildtype mice administered neutralizing Abs against type I IFN receptor. Interestingly, susceptibility to ZIKV clinical infection including weight loss and mortality each persists and is neither significantly improved nor worsened compared with isogenic L. monocytogenes–primed control mice. These data demonstrating persistent ZIKV clinical susceptibility despite reduced viral burden in mice with expanded virus-specific CD8+ T cells highlights the need for targeting other adaptive immune components in developing vaccines against ZIKV infection.
文章链接：https://www.jimmunol.org/content/205/2/447
订购详情：
| 产品名称 | 货号 | 规格 |
| InVivoMAb anti-mouse IFNAR-1 | BE0241 | 1/5/25/50/100mg |
| InVivoPlus anti-mouse IFNAR-1 | BP0241 | 1/5/25/50/100mg |
详情请咨询 BioXcell 中国授权代理-欣博盛生物科技
全国服务热线: 4006-800-892 邮箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029 上海: 021-34613729
广州：18024516375 香港: 852-69410778
代理品牌网站: www.nbs-bio.com
自主品牌网站: www.neobioscience.net